Form **PTO-1595** (Rev. 07/05) OMB No. 0651-0027 (exp. 6/30/2008)

11-21-2005

DEPARTMENT OF COMMERCE States Patent and Trademark Office

11/16 K RECC 111/11/11/11	03122260
To the Director of the U.S. Patent and Trademark Office: Pleas	e record the attached documents or the new address(es) below.
Name of conveying party(ies)	2. Name and address of receiving party(ies)
Novartis Finance Corporation	Name: Syngenta Investment Corporation
	Internal Address:
Additional name(s) of conveying party(ies) attached? Yes V No	
3. Nature of conveyance/Execution Date(s):	Street Address: 2200 Concord Pike
Execution Date(s) 3/1/2004	
Assignment Merger	City: Wilmington
Security Agreement Change of Name	Oity. Millington
☐ Joint Research Agreement	State: Delaware
Government Interest Assignment	Country: United States of America Zip: 19803
Executive Order 9424, Confirmatory License	
Other	Additional name(s) & address(es) attached? Yes Vo
	document is being filed together with a new application.
A. Patent Application No.(s)	B. Patent No.(s)
	5,662,898
Additional numbers at	lached? Yes VNo
5. Name and address to whom correspondence	6. Total number of applications and patents
concerning document should be mailed:	involved: 1
Name:Larry W. Stults, Esq.	7. Total fee (37 CFR 1.21(h) & 3.41) \$ 40.00
Internal Address: Syngenta Biotechnology, Inc.	Authorized to be charged by credit card
	Authorized to be charged to deposit account
Street Address: 3054 East Cornwallis Road	Enclosed
	None required (government interest not affecting title)
City: Research Triangle Park	8. Payment Information
	a. Credit Card Last 4 Numbers
State: North Carolina Zip:27709	Expiration Date
Phone Number: <u>919-541-8646</u>	b. Deposit Account Number 50-1744
Fax Number: 919-541-8689	,
Email Address: greg.warren@syngenta.com	Authorized User Name Gregory W. Warren
9. Signature: Justin Warren	Nevember 14, 2005
Signature	November 14, 2005 Date
Gregory W. Warren	Total number of pages including cover 4
Name of Person Signing	sheet, attachments, and documents:

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to: Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

11/17/2005 ECOOPER 00000146 501744 5662898

01 FC:8021

40.00 DA

ASSIGNMENT

Whereas, Novartis Finance Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, is the assignee and legal owner of the entire right, title and interest in each of the United States patents listed in Appendix B; and

Whereas, in accordance with a resolution of its Board of Directors made on October 31, 2000, Novartis Finance Corporation wishes to assign its entire interest in each of the United States patents listed in Appendix B and in certain related United States patents and patent applications to Syngenta Investment Corporation, 2200 Concord Pike, Wilmington, DE 19803, a corporation of Delaware, and said Syngenta Investment Corporation wishes to acquire Novartis Finance Corporation's interest in said patents and patent applications.

Now, therefore, Novartis Finance Corporation hereby assigns to Syngenta Investment Corporation and its successors and assigns its entire right, title and interest in (1) (a) each of the three hundred thirty-five (335) United States patents listed in Appendix B, (b) any and all applications for reissues of said patents, (c) any and all reissues of said patents that may be issued and/or granted, (d) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (e) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents) and (2) (a) any and all United States patent applications, whether pending or abandoned, that are continuations and divisions (including further continuations and divisions such as, but not limited to, continuations and divisions of continuations) of the applications which issued as the patents listed in Appendix B. (b) any and all United States patents that may have been or, in the future, that may be issued and/or granted on all of said applications, (c) any and all applications for reissues of said patents, (d) any and all reissues of said patents that may be issued and/or granted, (e) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (f) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), including, in the case of all patents (including reissue patents) within the scopes of (1) and (2), the right to sue, and to obtain damages, for past infringement, said right, title and interest conveyed herein by Novartis Finance Corporation to Syngenta Investment Corporation constituting the entire right, title and interest in said patents (including reissue patents), applications, extensions and reexamination certificates.

In witness whereof, Novartis Finance Corporation has caused this Assignment to be signed by its duly authorized corporate officer.

Signed this 1st day of March 2004.

Novartis Finance Corporation

Wayne P. Merkelson

Vice-President

PATENT REEL: 017230 FRAME: 0709

Appendix B

4,600,428	4,886,887	5,120,741	5,430,188
4,601,745	4,888,348	5,135,927	5,436,248
4,602,936	4,897,109	5,153,200	5,439,912
4,603,211	4,897,396	5,166,153	5,446,154
4,605,656	4,897,424	5,166,430	
4,608,372	4,900,827	5,169,951	5,447,935
4,612,037	4,902,340	5,175,293	5,447,945
4,612,395	4,904,778	5,179,094	5,451,595 5,457,376
4,618,360	4,908,467	5,183,492	5,4 57 ,276
4,623,382	4,914,098	5,190,928	5,466,785 5,477,003
4,629,810	4,918,088	5,194,628	5,477,002 5,479,059
4,632,695	4,918,230	5,204,100	5,478,958 5,481,013
4,671,819	4,919,704	5,209,771	5,481,013
4,674,229	4,919,935	5,217,871	5,484,918 5,480,605
4,681,619	4,921,980	5,232,898	5,489,695 5,403,033
4,686,294	4,925,840	5,237,084	5,493,032
4,692,524	4,925,842	5,245,040	5,496,848
4,693,741	4,925,876	5,250,556	5,506,099
4,693,745	4,931,439	5,250,557	5,508,184
4,705,800	4,931,560	5,250,559	5,508,402 5,514,705
4,707,182	4,931,581	5,254,739	5,514,795 5,514,846
4,709,092	4,935,051	5,262,386	5,514,816
4,727,186	4,938,797	5,266,554	5,519,026 5,510,125
4,729,190	4,939,257	5,266,585	5,519,125 5,521,153
4,753,954	4,944,790	5,274,100	5,521,153
4,758,667	4,948,798	5,276,186	5,521,195
4,759,793	4,952,726	5,280,041	5,523,311
4,766,253	4,958,030	5,281,718	5,527,760
4,780,125	4,959,096	5,286,709	5,527,917
4,780,551	4,962,126	5,296,449	5,530,195
4,798,688	4,968,344	5,302,605	5,536,726
4,810,724	4,978,383	5,302,607	5,536,900
4,812,164	4,989,741	5,310,721	5,538,979
4,831,148	4,992,434	5,322,853	5,541,148
4,833,255	4,996,325	5,324,842	5,541,310 5,545,630
4,847,258	4,997,941	5,332,717	5,545,630 5,553,360
4,849,007	4,997,967	5,350,689	5,552,368 5,554,640
4,849,009	5,002,604	5,373,013	5,554,619
4,849,219	5,002,606	5,384,321	5, 556,828 5,558,997
4,851,028	5,023,259	5,384,403	•
4,851,031	5,023,333	5,384,416	5,559,034 5,561,230
4,853,396	5,041,603	5,397,697	5,567,705
4,854,963	5,049,571	5,399,545	5,583,249
4,857,100	5,063,236	5,403,814	5,585,249 5,585,238
4,859,229	5,075,316	5,403,844	5,585,519
4,861,787	5,075,443	5,407,934	5,595,733
4,866,079	5,077,311	5,409,823	5,596,131
4,870,184	5,082,860	5,412,107	5,597,779
4,872,902	5,102,445	5,420,301	5,5 9 7,77 9 5,5 9 7,840
4,881,964	5,104,440	5,430,034	5,599,771
4,881,966	5,112,849	5,430,035	5,599,828
	·	· , · , · - ·	5,000,020

1

PATENT REEL: 017230 FRAME: 0710

Appendix B

5,721,364 5,880,328 5,723,491 5,882,869

5,925,367 5,929,102 5,942,662 5,945,437 5,955,274 5,955,362 5,958,835 5,981,582 5,990,383 6,017,850 6,017,851 6,018,105 6,034,083 6,048,824 6,057,490 6,066,596 6,071,698 6,083,881 6,091,004 6,103,667 6,107,279 6,107,544 6,117,670 6,117,892 6,130,236 6,137,033 6,147,282 D361,509 D364,956 End

2